Published in J Biol Chem on February 25, 2004
Role of receptor tyrosine kinase transmembrane domains in cell signaling and human pathologies. Biochemistry (2006) 1.96
Structural evidence for loose linkage between ligand binding and kinase activation in the epidermal growth factor receptor. Mol Cell Biol (2010) 1.63
Transmembrane helix dimerization: beyond the search for sequence motifs. Biochim Biophys Acta (2011) 1.26
Energetics of ErbB1 transmembrane domain dimerization in lipid bilayers. Biophys J (2009) 1.24
The extracellular domain of fibroblast growth factor receptor 3 inhibits ligand-independent dimerization. Sci Signal (2010) 1.22
Structural organization and interactions of transmembrane domains in tetraspanin proteins. BMC Struct Biol (2005) 1.19
A transmembrane domain and GxxxG motifs within L2 are essential for papillomavirus infection. J Virol (2012) 1.10
Physical-chemical principles underlying RTK activation, and their implications for human disease. Biochim Biophys Acta (2011) 1.06
Receptor tyrosine kinase transmembrane domains: Function, dimer structure and dimerization energetics. Cell Adh Migr (2010) 1.06
A structural perspective on the regulation of the epidermal growth factor receptor. Annu Rev Biochem (2015) 1.04
Single-spanning transmembrane domains in cell growth and cell-cell interactions: More than meets the eye? Cell Adh Migr (2010) 1.01
Polar residues in transmembrane helices can decrease electrophoretic mobility in polyacrylamide gels without causing helix dimerization. Biochim Biophys Acta (2009) 0.92
Specific inhibition of a pathogenic receptor tyrosine kinase by its transmembrane domain. Biochim Biophys Acta (2010) 0.91
Transmembrane helix-helix interactions involved in ErbB receptor signaling. Cell Adh Migr (2010) 0.89
The strong dimerization of the transmembrane domain of the fibroblast growth factor receptor (FGFR) is modulated by C-terminal juxtamembrane residues. Protein Sci (2009) 0.86
Multi-Tox: application of the ToxR-transcriptional reporter assay to the study of multi-pass protein transmembrane domain oligomerization. Biochim Biophys Acta (2011) 0.85
Strong dimerization of wild-type ErbB2/Neu transmembrane domain and the oncogenic Val664Glu mutant in mammalian plasma membranes. Biochim Biophys Acta (2014) 0.85
Molecular modeling of nearly full-length ErbB2 receptor. Biophys J (2004) 0.85
Targeting ERBB receptors shifts their partners and triggers persistent ERK signaling through a novel ERBB/EFNB1 complex. Cancer Res (2013) 0.84
Arginine mutations within a transmembrane domain of Tar, an Escherichia coli aspartate receptor, can drive homodimer dissociation and heterodimer association in vivo. Biochem J (2005) 0.80
Insight into the recognition patterns of the ErbB receptor family transmembrane domains: heterodimerization models through molecular dynamics search. Eur Biophys J (2008) 0.79
Molecular dynamics simulation approach for the prediction of transmembrane helix-helix heterodimers assembly. Eur Biophys J (2007) 0.79
The transmembrane domain of CEACAM1-4S is a determinant of anchorage independent growth and tumorigenicity. PLoS One (2012) 0.79
Neutralization of pro-inflammatory monocytes by targeting TLR2 dimerization ameliorates colitis. EMBO J (2016) 0.76
The Under-Appreciated Promiscuity of the Epidermal Growth Factor Receptor Family. Front Cell Dev Biol (2016) 0.75
The Dipole Potential Modifies the Clustering and Ligand Binding Affinity of ErbB Proteins and Their Signaling Efficiency. Sci Rep (2016) 0.75
A New Method to Study Heterodimerization of Membrane Proteins and its Application to Fibroblast Growth Factor Receptors. J Biol Chem (2016) 0.75
Ultrashort antibacterial and antifungal lipopeptides. Proc Natl Acad Sci U S A (2006) 2.15
Endotoxin (lipopolysaccharide) neutralization by innate immunity host-defense peptides. Peptide properties and plausible modes of action. J Biol Chem (2005) 1.72
T-cell inactivation and immunosuppressive activity induced by HIV gp41 via novel interacting motif. FASEB J (2006) 1.57
Conjugation of a magainin analogue with lipophilic acids controls hydrophobicity, solution assembly, and cell selectivity. Biochemistry (2002) 1.49
Can we predict biological activity of antimicrobial peptides from their interactions with model phospholipid membranes? Peptides (2003) 1.42
New lytic peptides based on the D,L-amphipathic helix motif preferentially kill tumor cells compared to normal cells. Biochemistry (2003) 1.37
Exploring peptide membrane interaction using surface plasmon resonance: differentiation between pore formation versus membrane disruption by lytic peptides. Biochemistry (2003) 1.33
The consequence of sequence alteration of an amphipathic alpha-helical antimicrobial peptide and its diastereomers. J Biol Chem (2002) 1.30
Lipopolysaccharide (Endotoxin)-host defense antibacterial peptides interactions: role in bacterial resistance and prevention of sepsis. Biochim Biophys Acta (2006) 1.29
Bestowing antifungal and antibacterial activities by lipophilic acid conjugation to D,L-amino acid-containing antimicrobial peptides: a plausible mode of action. Biochemistry (2003) 1.25
Energetics of ErbB1 transmembrane domain dimerization in lipid bilayers. Biophys J (2009) 1.24
A new group of antifungal and antibacterial lipopeptides derived from non-membrane active peptides conjugated to palmitic acid. J Biol Chem (2004) 1.23
A molecular mechanism for lipopolysaccharide protection of Gram-negative bacteria from antimicrobial peptides. J Biol Chem (2005) 1.23
Antimicrobial lipopolypeptides composed of palmitoyl Di- and tricationic peptides: in vitro and in vivo activities, self-assembly to nanostructures, and a plausible mode of action. Biochemistry (2008) 1.19
Effect of drastic sequence alteration and D-amino acid incorporation on the membrane binding behavior of lytic peptides. Biochemistry (2004) 1.18
Inhibition of tumor growth and elimination of multiple metastases in human prostate and breast xenografts by systemic inoculation of a host defense-like lytic peptide. Cancer Res (2006) 1.18
Transmembrane domains interactions within the membrane milieu: principles, advances and challenges. Biochim Biophys Acta (2011) 1.16
Suppression of human prostate tumor growth in mice by a cytolytic D-, L-amino Acid Peptide: membrane lysis, increased necrosis, and inhibition of prostate-specific antigen secretion. Cancer Res (2004) 1.15
Demonstrating the C-terminal boundary of the HIV 1 fusion conformation in a dynamic ongoing fusion process and implication for fusion inhibition. FASEB J (2007) 1.14
Specificity in transmembrane helix-helix interactions mediated by aromatic residues. J Biol Chem (2007) 1.13
Viral fusion proteins: multiple regions contribute to membrane fusion. Biochim Biophys Acta (2003) 1.12
The stability of the intact envelope glycoproteins is a major determinant of sensitivity of HIV/SIV to peptidic fusion inhibitors. J Mol Biol (2004) 1.10
A novel lytic peptide composed of DL-amino acids selectively kills cancer cells in culture and in mice. J Biol Chem (2003) 1.10
Structurally altered peptides reveal an important role for N-terminal heptad repeat binding and stability in the inhibitory action of HIV-1 peptide DP178. J Biol Chem (2006) 1.09
Lipid clustering by three homologous arginine-rich antimicrobial peptides is insensitive to amino acid arrangement and induced secondary structure. Biochim Biophys Acta (2010) 1.08
Thermodynamics of melittin binding to lipid bilayers. Aggregation and pore formation. Biochemistry (2009) 1.07
Conjugation of fatty acids with different lengths modulates the antibacterial and antifungal activity of a cationic biologically inactive peptide. Biochem J (2005) 1.06
A synergism between temporins toward Gram-negative bacteria overcomes resistance imposed by the lipopolysaccharide protective layer. J Biol Chem (2006) 1.06
D-alanylation of lipoteichoic acids confers resistance to cationic peptides in group B streptococcus by increasing the cell wall density. PLoS Pathog (2012) 1.05
Controlled alteration of the shape and conformational stability of alpha-helical cell-lytic peptides: effect on mode of action and cell specificity. Biochem J (2005) 1.05
Short native antimicrobial peptides and engineered ultrashort lipopeptides: similarities and differences in cell specificities and modes of action. Cell Mol Life Sci (2011) 1.04
In vitro activity and potency of an intravenously injected antimicrobial peptide and its DL amino acid analog in mice infected with bacteria. Antimicrob Agents Chemother (2004) 1.04
Characterization of the HIV N-terminal fusion peptide-containing region in context of key gp41 fusion conformations. J Biol Chem (2006) 1.02
Inhibition of fungal and bacterial plant pathogens in vitro and in planta with ultrashort cationic lipopeptides. Appl Environ Microbiol (2007) 1.01
pH-dependent antifungal lipopeptides and their plausible mode of action. Biochemistry (2005) 1.01
Functional and structural characterization of HIV-1 gp41 ectodomain regions in phospholipid membranes suggests that the fusion-active conformation is extended. J Mol Biol (2006) 1.00
Oncolytic activities of host defense peptides. Int J Mol Sci (2011) 1.00
Suppression of human solid tumor growth in mice by intratumor and systemic inoculation of histidine-rich and pH-dependent host defense-like lytic peptides. Cancer Res (2009) 1.00
Preassembly of membrane-active peptides is an important factor in their selectivity toward target cells. Biochemistry (2002) 1.00
C-terminal octylation rescues an inactive T20 mutant: implications for the mechanism of HIV/SIMIAN immunodeficiency virus-induced membrane fusion. J Biol Chem (2003) 0.99
Multifaceted action of Fuzeon as virus-cell membrane fusion inhibitor. Biochim Biophys Acta (2011) 0.99
HIV-1 gp41 transmembrane domain interacts with the fusion peptide: implication in lipid mixing and inhibition of virus-cell fusion. Biochemistry (2012) 0.99
Lipopolysaccharide, a key molecule involved in the synergism between temporins in inhibiting bacterial growth and in endotoxin neutralization. J Biol Chem (2008) 0.99
Comparative analysis of membrane-associated fusion peptide secondary structure and lipid mixing function of HIV gp41 constructs that model the early pre-hairpin intermediate and final hairpin conformations. J Mol Biol (2010) 0.99
Effect of the hydrophobicity to net positive charge ratio on antibacterial and anti-endotoxin activities of structurally similar antimicrobial peptides. Biochemistry (2010) 0.97
Parameters involved in antimicrobial and endotoxin detoxification activities of antimicrobial peptides. Biochemistry (2008) 0.97
Mechanistic and functional studies of the interaction of a proline-rich antimicrobial peptide with mammalian cells. J Biol Chem (2005) 0.96
On the interaction between gp41 and membranes: the immunodominant loop stabilizes gp41 helical hairpin conformation. J Mol Biol (2003) 0.96
Utilizing ESEEM spectroscopy to locate the position of specific regions of membrane-active peptides within model membranes. Biophys J (2005) 0.96
HIV-1 fusion peptide targets the TCR and inhibits antigen-specific T cell activation. J Clin Invest (2005) 0.96
Membrane-anchored HIV-1 N-heptad repeat peptides are highly potent cell fusion inhibitors via an altered mode of action. PLoS Pathog (2009) 0.95
W-Band pulse EPR distance measurements in peptides using Gd(3+)-dipicolinic acid derivatives as spin labels. Phys Chem Chem Phys (2011) 0.95
The HIV-1 gp41 N-terminal heptad repeat plays an essential role in membrane fusion. Biochemistry (2002) 0.95
Efficient clearance of Aspergillus fumigatus in murine lungs by an ultrashort antimicrobial lipopeptide, palmitoyl-lys-ala-DAla-lys. Antimicrob Agents Chemother (2008) 0.95
Impairment of innate immune killing mechanisms by bacteriostatic antibiotics. FASEB J (2007) 0.94
Hairpin folding of HIV gp41 abrogates lipid mixing function at physiologic pH and inhibits lipid mixing by exposed gp41 constructs. Biochemistry (2009) 0.93
Insights into the mechanism of HIV-1 envelope induced membrane fusion as revealed by its inhibitory peptides. Eur Biophys J (2011) 0.93
The HIV fusion peptide adopts intermolecular parallel beta-sheet structure in membranes when stabilized by the adjacent N-terminal heptad repeat: a 13C FTIR study. J Mol Biol (2005) 0.93
The C- and the N-terminal regions of glycoprotein 41 ectodomain fuse membranes enriched and not enriched with cholesterol, respectively. J Biol Chem (2004) 0.92
Membrane integration of a mitochondrial signal-anchored protein does not require additional proteinaceous factors. Biochem J (2012) 0.92
HIV-1 gp41 and TCRalpha trans-membrane domains share a motif exploited by the HIV virus to modulate T-cell proliferation. PLoS Pathog (2010) 0.92
Conformational stability and membrane interaction of the full-length ectodomain of HIV-1 gp41: implication for mode of action. Biochemistry (2009) 0.91
Quantitative proteomic analysis reveals formation of an EscL-EscQ-EscN type III complex in enteropathogenic Escherichia coli. J Bacteriol (2011) 0.91
Temporins and their synergism against Gram-negative bacteria and in lipopolysaccharide detoxification. Biochim Biophys Acta (2009) 0.90
Hetero-assembly between all-L- and all-D-amino acid transmembrane domains: forces involved and implication for inactivation of membrane proteins. J Mol Biol (2004) 0.90
Artificial beta-defensin based on a minimal defensin template. Biochem J (2009) 0.90
Effect of natural L- to D-amino acid conversion on the organization, membrane binding, and biological function of the antimicrobial peptides bombinins H. Biochemistry (2006) 0.90
The identification of a minimal dimerization motif QXXS that enables homo- and hetero-association of transmembrane helices in vivo. J Biol Chem (2005) 0.88
New insights into the mechanism of virus-induced membrane fusion. Trends Biochem Sci (2002) 0.87
Investigation of model membrane disruption mechanism by melittin using pulse electron paramagnetic resonance spectroscopy and cryogenic transmission electron microscopy. J Phys Chem B (2011) 0.87
Effect of PhoP-PhoQ activation by broad repertoire of antimicrobial peptides on bacterial resistance. J Biol Chem (2011) 0.87
Viral envelope protein folding and membrane hemifusion are enhanced by the conserved loop region of HIV-1 gp41. FASEB J (2011) 0.86
Structures and mode of membrane interaction of a short alpha helical lytic peptide and its diastereomer determined by NMR, FTIR, and fluorescence spectroscopy. Eur J Biochem (2002) 0.86
Virus-cell and cell-cell fusion mediated by the HIV-1 envelope glycoprotein is inhibited by short gp41 N-terminal membrane-anchored peptides lacking the critical pocket domain. FASEB J (2010) 0.86
D-enantiomer peptide of the TCRalpha transmembrane domain inhibits T-cell activation in vitro and in vivo. FASEB J (2005) 0.86
A structurally altered D,L-amino acid TCRalpha transmembrane peptide interacts with the TCRalpha and inhibits T-cell activation in vitro and in an animal model. Biochemistry (2007) 0.85
Fatty acids can substitute the HIV fusion peptide in lipid merging and fusion: an analogy between viral and palmitoylated eukaryotic fusion proteins. J Mol Biol (2007) 0.85
Ultrashort peptide bioconjugates are exclusively antifungal agents and synergize with cyclodextrin and amphotericin B. Antimicrob Agents Chemother (2011) 0.85
Assembly of the TLR2/6 transmembrane domains is essential for activation and is a target for prevention of sepsis. J Immunol (2013) 0.85
Characterization of the interacting domain of the HIV-1 fusion peptide with the transmembrane domain of the T-cell receptor. Biochemistry (2008) 0.85
The composition rather than position of polar residues (QxxS) drives aspartate receptor transmembrane domain dimerization in vivo. Biochemistry (2004) 0.85
The GBS PI-2a pilus is required for virulence in mice neonates. PLoS One (2011) 0.85
How structure correlates to function for membrane associated HIV-1 gp41 constructs corresponding to the N-terminal half of the ectodomain. J Mol Biol (2003) 0.84
Trivalent ultrashort lipopeptides are potent pH dependent antifungal agents. J Med Chem (2012) 0.84
Synthetic ultrashort cationic lipopeptides induce systemic plant defense responses against bacterial and fungal pathogens. Appl Environ Microbiol (2009) 0.84
Conolysin-Mt: a conus peptide that disrupts cellular membranes. Biochemistry (2007) 0.84
Ranacyclins, a new family of short cyclic antimicrobial peptides: biological function, mode of action, and parameters involved in target specificity. Biochemistry (2003) 0.84
A highly conserved sequence associated with the HIV gp41 loop region is an immunomodulator of antigen-specific T cells in mice. Blood (2013) 0.83
HIV-1 fusion protein exerts complex immunosuppressive effects. Trends Biochem Sci (2013) 0.82
Chirality-independent protein-protein recognition between transmembrane domains in vivo. J Mol Biol (2002) 0.82
Sendai virus N-terminal fusion peptide consists of two similar repeats, both of which contribute to membrane fusion. Eur J Biochem (2002) 0.82
Suppression of soft tissue sarcoma growth by a host defense-like lytic peptide. PLoS One (2011) 0.82
A combined pulse EPR and Monte Carlo simulation study provides molecular insight on peptide-membrane interactions. J Phys Chem B (2009) 0.81
Oncolytic designer host defense peptide suppresses growth of human liposarcoma. Int J Cancer (2010) 0.81
Arginine mutations within a transmembrane domain of Tar, an Escherichia coli aspartate receptor, can drive homodimer dissociation and heterodimer association in vivo. Biochem J (2005) 0.80
Single-particle tracking reveals switching of the HIV fusion peptide between two diffusive modes in membranes. J Phys Chem B (2013) 0.79
Temporins A and B stimulate migration of HaCaT keratinocytes and kill intracellular Staphylococcus aureus. Antimicrob Agents Chemother (2014) 0.79
Inhibition of HIV-1 envelope glycoprotein-mediated cell fusion by a DL-amino acid-containing fusion peptide: possible recognition of the fusion complex. J Biol Chem (2004) 0.79